Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 793005, "name": "Glaxosmi. Pharma", "stock_name": "Glaxosmi. Pharma", "full_name": "Glaxosmithkline Pharmaceuticals Ltd", "name_url": "stocks-analysis/glaxosmi-pharma", "exchange": 1, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "2,600.00", "chg": -38.6, "chgp": "-1.46%", "dir": -1, "prev_price": "2,638.60", "mcapval": "44,045.57 Cr", "mcap": "Mid Cap", "scripcode": 500660, "symbol": "GLAXO", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE159A01016", "curr_date": "Feb 24", "curr_time": "", "bse_nse_vol": "16.52 k", "exc_status": "Active", "traded_date": "Feb 24, 2026", "traded_date_str": "2026 02 24", "score": "", "scoreText": "", "Live": 0, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3850556", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_mojoScore_3850556.png", "date": "2026-02-23 10:10:51", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3850536", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_mojoScore_3850536.png", "date": "2026-02-22 10:10:29", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Glaxosmithkline Pharmaceuticals Gains 4.35%: 4 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-gains-435-4-key-factors-driving-the-week-3839727", "imagepath": "", "date": "2026-02-14 15:02:20", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>9 Feb:</strong> Q3 FY26 results reveal strong margins amid valuation concerns</p>\n <p><strong>9 Feb:</strong> Technical momentum shifts to mildly bearish with mixed signals</p>\n <p><strong>10 Feb:</strong> Intraday high surge of 6.14% to Rs.2,632.9</p>\n <p><strong>10 Feb:</strong> Reports strong quarterly financial turnaround with record revenue and profit</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,485.85</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Clo..." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3832616", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_mojoScore_3832616.png", "date": "2026-02-11 10:11:06", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift from the previous Hold status. However, the analysis and financial metrics discussed here represent the stock’s current position as of 11 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Hits Intraday High with 6.14% Surge", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-hits-intraday-high-with-614-surge-3830214", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_priceRelatedfactors_3830214.png", "date": "2026-02-10 09:32:54", "description": "Glaxosmithkline Pharmaceuticals Ltd recorded a robust intraday performance on 10 Feb 2026, surging 6.14% to touch a day’s high of Rs 2,632.9. The stock outperformed its sector and the broader market, reflecting heightened trading activity and notable volatility throughout the session." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Reports Strong Quarterly Financial Turnaround", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-reports-strong-quarterly-financial-turnaround-3829479", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_fintrenddot_3829479.png", "date": "2026-02-10 08:00:23", "description": "Glaxosmithkline Pharmaceuticals Ltd has delivered a robust quarterly performance for the December 2025 quarter, marking a significant positive shift in its financial trend after a period of stagnation. The company posted record-high revenues and profitability metrics, signalling renewed operational strength despite some lingering concerns over liquidity and debtor management." }, { "title": "Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-glaxosmithkline-pharmaceuticals-ltd-latest-results-good-or-bad-3829079", "imagepath": "", "date": "2026-02-09 19:17:12", "description": "GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape. The company reported a net profit of ₹257.49 crores, reflecting a year-on-year increase of 1.98% and a quarter-on-quarter growth of 25.60%. This growth in net profit can be attributed to margin expansion, with the operating margin reaching 34.26%, up 243 basis points year-on-year. \n\nHowever, the revenue performance presents a contrasting picture. The company recorded net sales of ₹979.94 crores, which is a decline of 3.05% year-on-year but a significant sequential increase of 21.71% from the previous quarter. This volatility in revenue highlights challenges in volume growth, despite the company maintaining robust pricing power.\n\nThe operational efficiency is further underscored by a high return on equity (ROE) of 59.34%, which positions the company favorably within the industry. The balance s..." }, { "title": "GlaxoSmithKline Pharmaceuticals Q3 FY26: Strong Margins Mask Valuation Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/glaxosmithkline-pharmaceuticals-q3-fy26-strong-margins-offset-by-valuation-concerns-3829018", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_quaterlyResult_3829018.png", "date": "2026-02-09 18:02:15", "description": "GlaxoSmithKline Pharmaceuticals Ltd. reported a robust third quarter for FY2026, with net profit surging 28.60% year-on-year to ₹295.62 crores and 14.81% sequentially from Q2 FY26. The pharmaceutical major, commanding a market capitalisation of ₹44,413 crores, demonstrated impressive operational efficiency with operating margins expanding to 35.66%, the highest in recent quarters. However, the stock declined 2.89% following the results announcement, trading at ₹2,590.00 on February 13, reflecting investor concerns about stretched valuations and modest long-term growth trajectory." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-3827870", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Glaxosmithkline_technicaldot_3827870.png", "date": "2026-02-09 08:02:00", "description": "Glaxosmithkline Pharmaceuticals Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a recent day gain of 1.75%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of the stock, contextualising its performance against broader market trends and sectoral benchmarks." } ], "total": 5159, "sid": "793005", "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005" }, "announcements": [ { "details": "GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Change of name of Registrar and Transfer Agent'.", "source": "NSE", "caption": "GlaxoSmithKline Pharmaceuticals Limited - Updates", "datetime": "09-Dec-2019" }, { "details": "GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Submission of Disclosure on Related Party Transactions '.", "source": "NSE", "caption": "GlaxoSmithKline Pharmaceuticals Limited - Updates", "datetime": "30-Oct-2019" }, { "details": "GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Results publication '.", "source": "NSE", "caption": "GlaxoSmithKline Pharmaceuticals Limited - Updates", "datetime": "23-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25", "dt": "2025-05-30", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18", "dt": "2018-09-11", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

9 Feb: Q3 FY26 results reveal strong margins amid valuation concerns

9 Feb: Technical momentum shifts to mildly bearish with mixed signals

10 Feb: Intraday high surge of 6.14% to Rs.2,632.9

10 Feb: Reports strong quarterly financial turnaround with record revenue and profit

Week Open

Rs.2,485.85

Week Clo...

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-02-11 10:11:06

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift from the previous Hold status. However, the analysis and financial metrics discussed here represent the stock’s current position as of 11 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Hits Intraday High with 6.14% Surge

2026-02-10 09:32:54

Glaxosmithkline Pharmaceuticals Ltd recorded a robust intraday performance on 10 Feb 2026, surging 6.14% to touch a day’s high of Rs 2,632.9. The stock outperformed its sector and the broader market, reflecting heightened trading activity and notable volatility throughout the session.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Reports Strong Quarterly Financial Turnaround

2026-02-10 08:00:23

Glaxosmithkline Pharmaceuticals Ltd has delivered a robust quarterly performance for the December 2025 quarter, marking a significant positive shift in its financial trend after a period of stagnation. The company posted record-high revenues and profitability metrics, signalling renewed operational strength despite some lingering concerns over liquidity and debtor management.

Read full news article

Are Glaxosmithkline Pharmaceuticals Ltd latest results good or bad?

2026-02-09 19:17:12

GlaxoSmithKline Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate a complex operational landscape. The company reported a net profit of ₹257.49 crores, reflecting a year-on-year increase of 1.98% and a quarter-on-quarter growth of 25.60%. This growth in net profit can be attributed to margin expansion, with the operating margin reaching 34.26%, up 243 basis points year-on-year. However, the revenue performance presents a contrasting picture. The company recorded net sales of ₹979.94 crores, which is a decline of 3.05% year-on-year but a significant sequential increase of 21.71% from the previous quarter. This volatility in revenue highlights challenges in volume growth, despite the company maintaining robust pricing power. The operational efficiency is further underscored by a high return on equity (ROE) of 59.34%, which positions the company favorably within the industry. The balance s...

Read full news article

GlaxoSmithKline Pharmaceuticals Q3 FY26: Strong Margins Mask Valuation Concerns

2026-02-09 18:02:15

GlaxoSmithKline Pharmaceuticals Ltd. reported a robust third quarter for FY2026, with net profit surging 28.60% year-on-year to ₹295.62 crores and 14.81% sequentially from Q2 FY26. The pharmaceutical major, commanding a market capitalisation of ₹44,413 crores, demonstrated impressive operational efficiency with operating margins expanding to 35.66%, the highest in recent quarters. However, the stock declined 2.89% following the results announcement, trading at ₹2,590.00 on February 13, reflecting investor concerns about stretched valuations and modest long-term growth trajectory.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-09 08:02:00

Glaxosmithkline Pharmaceuticals Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a recent day gain of 1.75%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of the stock, contextualising its performance against broader market trends and sectoral benchmarks.

Read full news article